Compatibility of multiple herbal components in Erxian Decoction, a Chinese medicinal formula, for treating osteoporosis

European Journal of Integrative Medicine

Volumn 4, Issue 2, 2012, Pages

  Sze, Stephen Cho Wing ^a   Ip, Chun Wai ^a   Ng, Tzi Bun ^b   Zhang, Kalin Yanbo ^a   Zhang, Zhang Jin ^a   Cheung, Ho Pan ^a   Cheng, Chris Lok Yin ^a   Tong, Yao ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Prince of Wales Hospital   (Hong Kong)

Author keywords

Chinese medicines; Erxian Decoction; Menopause; Osteoporosis

Indexed keywords

ANGELICA SINENSIS EXTRACT; CHINESE DRUG; CORTEX PHELLODENDRI EXTRACT; ERXIAN DECOCTION; HERBA EPIMEDII EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NFATC1 PROTEIN; OSTEOPROTEGERIN; PLANT EXTRACT; PROTEIN; PROTEIN C FOS; RADIX MORINDAE OFFICINALIS EXTRACT; RHIZOME ANEMARRHENAE EXTRACT; RHIZOME CURCULIGINIS EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHINESE MEDICINE; CONTROLLED STUDY; DOWN REGULATION; DRUG SCREENING; FETUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

EID: 84862777533     PISSN: 18763820     EISSN: 18763839     Source Type: Journal    
DOI: 10.1016/j.eujim.2012.01.006     Document Type: Article

References (39)

1. Bhalla A.K. Management of osteoporosis in a pre-menopausal woman. Best Pract Res Clin Rheumatol 2010, 24(3):313-327.
2. Borrelli F., Ernst E. Alternative and complementary therapies for the menopause. Maturitas 2010, 66(4):333-343.
3. Adler R.A. The need for increasing awareness of osteoporosis in men. Clin Cornerstone 2006, 8(Suppl. 3):S7-S13.
4. McNamara L.M. Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 2010, 7(44):353-372.
5. Weitzmann M.N., Roggia C., Toraldo G., Weitzmann L., Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002, 110(11):1643-1650.
6. Orlic I., Borovecki F., Simic P., Vukicevic S. Gene expression profiling in bone tissue of osteoporotic mice. Arh Hig Rada Toksikol 2007, 58(1):3-11.
7. Sato T., Watanabe K., Masuhara M., Hada N., Hakeda Y. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. J Bone Miner Metab 2007, 25(1):19-27.
8. Yano K., Tsuda E., Washida N., Kobayashi F., Goto M., Harada A., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999, 14(4):518-527.
9. Sarma U., Flanagan A.M. Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures. Blood 1996, 88(7):2531-2540.
10. Lerner U.H. Bone remodeling in post-menopausal osteoporosis. J Dent Res 2006, 85(7):584-595.
11. Eriksen E.F., Hodgson S.F., Eastell R., Cedel S.L., O'Fallon W.M., Riggs B.L. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res 1990, 5(4):311-319.
12. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005, 115(12):3318-3325.
13. Asagiri M., Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007, 40(2):251-264.
14. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000, 97(4):1566-1571.
15. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13(18):2412-2424.
16. Johnson R.S., Spiegelman B.M., Papaioannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 1992, 71(4):577-586.
17. Choi H.J., Park Y.R., Nepal M., Choi B.Y., Cho N.P., Choi S.H., et al. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. Eur J Pharmacol 2010, 636(1-3):28-35.
18. Rao A., Luo C., Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997, 15:707-747.
19. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3(6):889-901.
20. Davis S.R., Jane F. Drugs for the treatment of menopausal symptoms. Expert Opin Pharmacother 2010, 11(8):1329-1341.
21. Studd J. Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. Climacteric 2009, 12(3):206-209.
22. Lumachi F., Frigo A.C., Basso U., Tombolan V., Ermani M. Estrogen therapy and risk of breast cancer in postmenopausal women: a case-control study and results of a multivariate analysis. Menopause 2010, 17(3):524-528.
23. Sze S.C., Tong Y., Zhang Y.B., Zhang Z.J., Lau A.S., Wong H.K., et al. A novel mechanism: Erxian Decoction, a Chinese medicine formula, for relieving menopausal syndrome. J Ethnopharmacol 2009, 123(1):27-33.
24. Qin L., Han T., Zhang Q., Cao D., Nian H., Rahman K., et al. Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula. J Ethnopharmacol 2008, 118(2):271-279.
25. Zhang H., Xing W.W., Li Y.S., Zhu Z., Wu J.Z., Zhang Q.Y., et al. Effects of a traditional Chinese herbal preparation on osteoblasts and osteoclasts. Maturitas 2008, 61(4):334-339.
26. Tsuji-Naito K. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation. Bioorg Med Chem 2008, 16(20):9176-9183.
27. Wattel A., Kamel S., Prouillet C., Petit J.P., Lorget F., Offord E., et al. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. J Cell Biochem 2004, 92(2):285-295.
28. Nian H., Qin L.P., Zhang Q.Y., Zheng H.C., Yu Y., Huang B.K. Antiosteoporotic activity of Er-Xian Decoction, a traditional Chinese herbal formula, in ovariectomized rats. J Ethnopharmacol 2006, 108(1):96-102.
29. Michael H., Harkonen P.L., Vaananen H.K., Hentunen T.A. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 2005, 20(12):2224-2232.
30. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111(8):1221-1230.
31. Hopwood B., Tsykin A., Findlay D.M., Fazzalari N.L. Gene expression profile of the bone microenvironment in human fragility fracture bone. Bone 2009, 44(1):87-101.
32. Srivastava S., Weitzmann M.N., Kimble R.B., Rizzo M., Zahner M., Milbrandt J., et al. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J Clin Invest 1998, 102(10):1850-1859.
33. Ye H.Y., Lou Y.J. Estrogenic effects of two derivatives of icariin on human breast cancer MCF-7 cells. Phytomedicine 2005, 12(10):735-741.
34. Li H., Miyahara T., Tezuka Y., Tran Q.L., Seto H., Kadota S. Effect of berberine on bone mineral density in SAMP6 as a senile osteoporosis model. Biol Pharm Bull 2003, 26(1):110-111.
35. Ulrich-Merzenich G., Panek D., Zeitler H., Vetter H., Wagner H. Drug development from natural products: exploiting synergistic effects. Indian J Exp Biol 2010, 48(3):208-219.
36. Rahman M.M., Bhattacharya A., Fernandes G. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J Cell Physiol 2008, 214(1):201-209.
37. Xie F., Wu C.F., Lai W.P., Yang X.J., Cheung P.Y., Yao X.S., et al. The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro. Evid Based Complement Alternat Med 2005, 2(3):353-361.
38. Jiao L., Cao D.P., Qin L.P., Han T., Zhang Q.Y., Zhu Z., et al. Antiosteoporotic activity of phenolic compounds from Curculigo orchioides. Phytomedicine 2009, 16(9):874-881.
39. Wu Y.B., Zheng C.J., Qin L.P., Sun L.N., Han T., Jiao L., et al. Antiosteoporotic activity of anthraquinones from Morinda officinalis on osteoblasts and osteoclasts. Molecules 2009, 14(1):573-583.